OTC · BTTAY
Healthcare · Biotechnology
$24.21
Down-$0.02 (-0.10%)
Updated Sep 14, 2026, 6:35 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BTTAY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning BTTAY.
BTTAY research
Company profile and research snapshot.
BIOTEST AG UNSP/ADR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 3, 2024 | PARETO SECURITIES AS | Hold | — |
| Jul 2, 2024 | PARETO SECURITIES AS | Hold | — |
| Apr 1, 2023 | PARETO SECURITIES AS | Hold | — |
| Apr 1, 2023 | PARETO SECURITIES AS | Hold | — |
| Mar 31, 2023 | PARETO SECURITIES AS | Hold | — |
No generated briefing is available yet.
GlobeNewswire Inc. · May 22, 2025
The hypofibrinogenemia market is expected to grow significantly from 2025 to 2034, driven by the introduction of new therapies and an increase in the number of cases. Key companies working in this domain include CSL Behring, Octapharma, and Biotest AG.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BTTAY.
No results
No recent SID articles mention BTTAY.
